Skip to main content
. 2016 Apr 25;7(23):34617–34629. doi: 10.18632/oncotarget.8964

Figure 1. Farnesoid X receptor agonist GW4064 or CDCA enhances the sensitivity of GBC-SD and RBE cells to CDDP.

Figure 1

A. Cell viability in GBC-SD, SGC996, RBE and QBC939 cells treated with CDDP for 48h. Columns, mean of three experiments; bars, SD. *P <0.05, treatment group compared with control group. B, C. Cell viability in GBC-SD (B) and RBE (C) cells treated with GW4064 or CDCA for 48h. Columns, mean of three experiments; bars, SD. *P <0.05, treatment group compared with control group. D, E. Cell viability in GBC-SD (D) and RBE (E) cells treated with CDDP alone, GW4064 alone or CDDP/GW4064 co-treatment for 48 h. Columns, mean of three experiments; bars, SD. *P <0.05, combination treatment group compared with CDDP-alone group. F, G. Cell viability in GBC-SD (F) and RBE (G) cells treated with CDDP alone, CDCA alone or CDDP/CDCA co-treatment for 48 h. Columns, mean of three experiments; bars, SD. *P <0.05, combination treatment group compared with CDDP-alone group.